Arch Biopartners (TSE:ARCH)
:ARCH
Want to see TSE:ARCH full AI Analyst Report?
ARCH Stock Chart & Stats
C$1.37
-C$0.06(-3.14%)
At close: 4:00 PM EST
C$1.37
-C$0.06(-3.14%)
Day’s Range― - ―
52-Week RangeC$0.46 - C$1.95
Previous CloseN/A
Volume5.12K
Average Volume (3M)43.97K
Market Cap
C$32.27M
Enterprise ValueC$34.90M
Total Cash (Recent Filing)C$4.16K
Total Debt (Recent Filing)C$2.63M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Jun 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding67,933,290
10 Day Avg. Volume31,059
30 Day Avg. Volume43,967
Financial Highlights & Ratios
PEG Ratio0.88
Price to Book (P/B)-21.63
Price to Sales (P/S)0.00
P/FCF Ratio-53.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.16
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform-focused PipelineArch’s DPEP-1 platform plus an extracellular-histone antibody program provide scientific optionality across multiple indications. A validated platform can generate multiple development candidates, improving licensing leverage and long-term partner interest if clinical signals emerge.
Partnering/out-licensing ModelA partnership/out-licensing strategy is durable for a small clinical-stage biotech: it avoids building commercial infrastructure, lets the company monetize assets via upfront/milestone/royalty streams, and can extend runway while focusing R&D on high-value programs.
Targeting Acute/inflammatory MarketsTargeting acute and inflammatory syndromes addresses persistent unmet medical needs with sizable addressable markets and potential for expedited regulatory pathways. Success here can produce enduring demand and recurring clinical use across hospital and emergency care settings.
Bears Say
No Product RevenueZero TTM revenue means the company lacks internal product cash flows to fund development. Over a multi-month horizon this increases dependence on financings or partners, raises dilution risk, and limits the firm’s ability to self-fund trials or scale programs without external capital.
Persistent Cash BurnConsistent negative operating and free cash flow (~-$1.5M TTM) indicates the company is spending to advance clinical assets without offsetting inflows. Continued burn necessitates repeat fundraising, reducing strategic flexibility and elevating execution risk if funding channels tighten.
Fragile Balance SheetNegative equity, material debt and minimal assets constrain borrowing capacity and worsen solvency risk. This fragile capital structure limits ability to absorb clinical setbacks, increases likelihood of dilutive financing, and pressures near-term strategic choices and partner negotiations.
Arch Biopartners News
ARCH FAQ
What was Arch Biopartners’s price range in the past 12 months?
Arch Biopartners lowest stock price was C$0.46 and its highest was C$1.95 in the past 12 months.
What is Arch Biopartners’s market cap?
Arch Biopartners’s market cap is C$32.27M.
When is Arch Biopartners’s upcoming earnings report date?
Arch Biopartners’s upcoming earnings report date is Jun 02, 2026 which is in 36 days.
How were Arch Biopartners’s earnings last quarter?
Currently, no data Available
Is Arch Biopartners overvalued?
According to Wall Street analysts Arch Biopartners’s price is currently Overvalued.
Does Arch Biopartners pay dividends?
Arch Biopartners does not currently pay dividends.
What is Arch Biopartners’s EPS estimate?
Arch Biopartners’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arch Biopartners have?
Arch Biopartners has 67,933,290 shares outstanding.
What happened to Arch Biopartners’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Arch Biopartners?
Currently, no hedge funds are holding shares in TSE:ARCH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arch Biopartners Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.44%
12-Months-Change
Fundamentals
Return on Equity
72.34%
Trailing 12-Months
Asset Growth
-95.31%
Trailing 12-Months
Company Description
Arch Biopartners
Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, a drug candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The company is based in Toronto, Canada.
Technical Analysis
Satellos Bioscience
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
ME Therapeutics Holdings, Inc.
―
Onco-Innovations Ltd.
―
Options Prices
Currently, No data available
---